FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen ...

Innate Pharma continues its slow rollout of promising clinical candidates, with 2025 set for key milestones. Read more about IPHA stock here.

LUND, SE / ACCESS Newswire / March 21, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech ...

The firm is also shuttering its allogeneic cell therapy platform and has tasked a new CEO to lead the company through a merger.

Therapy-related B-cell acute lymphoblastic leukemia (B-ALL), a rare form of acute lymphoblastic leukemia (ALL), may develop in patients receiving cytotoxic treatments for a prior malignancy, according ...

Researchers have revealed a new finding that could improve cancer care immunotherapy treatments, particularly for CLL and ...

The data from the Phase 1/1b clinical trial of soquelitinib in patients with T cell lymphoma continues to demonstrate strong indications of anti-tumor activity in a significant number of patients,” ...

Under the terms of the deal, Sanofi will pay $600 million upfront to buy an affiliate of the California-based biotech, called ...

Lead Author Abstract Title Presentation Details Pro. Jie Hu 67P - A Phase II Study of SunvozertinibCombined with Anlotinib in ...

-- Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an overall response rate of 91% and composite complete ...

Final guidance published today recommends lisocabtagene maraleucel (also known as liso-cel or Breyanzi, made by Bristol Myers ...